Avidity Biosciences, Inc. — Director's Dealing 2021

Mar 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2021-03-16

Reporting Person: LEVIN ARTHUR A (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-05	Common Stock	G	37022	$0.00	Disposed	273872	Indirect
2021-03-05	Common Stock	G	37022	$0.00	Acquired	37022	Indirect
2021-03-16	Common Stock	M	2625	$1.24	Acquired	2625	Direct
2021-03-16	Common Stock	M	1975	$0.53	Acquired	4600	Direct
2021-03-16	Common Stock	S	4600	$27.8655	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-16	Stock Option (Right to Buy)	$1.24	M	2625	Disposed	2030-02-18	Common Stock (2625)	Direct
2021-03-16	Stock Option (Right to Buy)	$0.53	M	1975	Disposed	2027-08-28	Common Stock (1975)	Direct

Footnotes

F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.8571 to $27.8739. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.

F4: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.